ABCR  Vol.2 No.4 , October 2013
Early Results of Omitting Completion Axillary Lymph Node Dissection in Sentinel Lymph Node Metastasis-Positive Breast Cancer Patients

Background: We investigated the early results of omitting completion axillary lymph node dissection (ALND) for axillary node metastasis-negative (N0), sentinel node (SN) metastasis-positive breast cancer patients. Patients and Methods: 489 patients had invasive N0 breast cancer treated without completion ALND, regardless of their SN metastasis status. Analyses included the associations between the SN metastasis status, clinicopathological findings and recurrence, between recurrence and clinicopathological findings, and recurrence-free survival. Results: 430 patients were SN biopsy (SNB)-negative, and 59 were SNB-positive. The SNB-positive patients received significantly more potent adjuvant therapy than the SNB-negative patients. Median follow-up was 3.7 years, and the axillary node recurrence was seen in 6 patients (1.2%) and recurrence in 21 patients. The SN status showed no associations with the clinicopathological findings or recurrence. Univariate analysis showed recurrence was associated with absence of hormonal therapy, ER-negative, PgR-negative, HER2-positive or triple-negative (TNBC) disease, a tumor ≥2.1 cm and higher nuclear grade. Multivariate analysis showed recurrence was associated with absence of hormonal therapy and a tumor ≥2.1 cm. Cox proportional hazards model showed recurrence was extremely early in ER-negative and TNBC patients. Conclusion: Completion ALND can be skipped in N0 breast cancer patients even if they are SNB-positive, but adjuvant therapy is essential.

Cite this paper
Honda, J. , Matsuoka, H. , Hirose, C. , Nagao, T. , Yoshida, T. , Takahashi, M. , Imoto, I. and Sasa, M. (2013) Early Results of Omitting Completion Axillary Lymph Node Dissection in Sentinel Lymph Node Metastasis-Positive Breast Cancer Patients. Advances in Breast Cancer Research, 2, 126-132. doi: 10.4236/abcr.2013.24021.
[1]   T. Kim, A. E. Giuliano and G. H. Lyman, “Lymphatic Mapping and Sentinel Lymph Node Biopsy in Early-Stage Breast Carcinoma: A Metaanalysis,” Cancer, Vol. 106, No. 1, 2006, pp. 4-16. 10.1002/cncr.21568

[2]   M. R. Kell, J. P. Burke, M. Barry and M. Morrow, “Outcome of Axillary Staging in Early Breast Cancer: A Meta-Analysis,” Breast Cancer Research and Treatment, Vol. 120, No. 2, 2010, pp. 441-447.

[3]   G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. 3rd Benson, D. C. Bodurka, H. J. Burstein, A. V. Cochran, H. S. 3rd Cody, S. B. Edge, S. Galper, J. A. Hayman, T. Y. Kim, C. L. Perkins, D. A. Podoloff, V. H. Sivasubramaniam, R. R. Turner, R. Wahl, D. L. Weaver, A. C. Wolff and E. P. Winer, “American Society of Clinical Oncology: American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer,” Journal of Clinical Oncology, Vol. 23, No. 30, 2005, pp. 7703-7720.

[4]   A. E. Giuliano, K. K. Hunt, K. V. Ballman, P. D. Beitsch, P. W. Whitworth, P. W. Blumencranz, A. M. Leitch, S. Saha, L. M. McCall and M. Morrow, “Axillary Dissection vs No Axillary Dissection in Women with Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial,” Journal of American Medical Association, Vol. 305, No. 6, 2011, pp. 569-575. 10.1001/ jama.2011.90

[5]   “National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology. Breast Cancer. ver. 1,” 2013.

[6]   B. Fisher, J. H. Jeong, S. Anderson, J. Bryant, E. R. Fisher and N. Wolmark, “Twenty-Five-Year Follow-Up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation,” New England Journal of Medicine, Vol. 347, No. 8, 2002, pp. 567-575.

[7]   J. M. Guenther, N. M. Hansen, L. A. DiFronzo, A. E. Giuliano, J. C. Collins, B. L. Grube and T. X. O’Connell, “Axillary Dissection Is Not Required for All Patients with Breast Cancer and Positive Sentinel Nodes,” Archives of Surgery, Vol. 138, No. 1, 2003, pp. 52-56. archsurg.138.1.52

[8]   J. S. Fant, M. D. Grant, S. M. Knox, S. A. Livingston, K. Ridl, R. C. Jones and J. A. Kuhn, “Preliminary Outcome Analysis in Patients with Breast Cancer and a Positive Sentinel Lymph Node Who Declined Axillary Dissection,” Annals of Surgical Oncology, Vol. 10, No. 2, 2003, pp. 126-130. 10.1245/ ASO.2003.04.022

[9]   M. Minato, C. Hirose, M. Sasa, H. Nishitani, Y. Hirose and T. Morimoto, “ 3-Dimensional Computed Tomography Lymphography-Guided Identification of Sentinel Lymph Nodes in Breast Cancer Patients Using Subcutaneous Injection of Nonionic Contrast Medium: A Clinical Trial,” Journal of Computer Assisted Tomography, Vol. 28, No. 1, 2004, pp. 46-51.

[10]   M. Takahashi, M. Sasa, C. Hirose, S. Hisaoka, M. Taki, T. Hirose and Y. Bando, “Clinical Efficacy and Problems with CT Lymphography in Identifying the Sentinel Node in Breast Cancer,” World Journal of Surgical Oncology, Vol. 6, 2008, p. 57.

[11]   V. Galimberti, E. Botteri, C. Chifu, O. Gentilini, A. Luini, M. Intra, P. Baratella, M. Sargenti, S. Zurrida, P. Veronesi, N. Rotmensz, G. Viale, A. Sonzogni, M. Colleoni and U. Veronesi, “Can We Avoid Axillary Dissection in the Micrometastatic Sentinel Node in Breast Cancer?” Breast Cancer Research and Treatment, Vol. 131, No. 3, 2012, pp. 819-825.

[12]   K. Y. Bilimoria, D. J. Bentrem, N. M. Hansen, K. P. Bethke, A. W. Rademaker, C. Y. Ko, D. P. Winchester and D. J. Winchester, “Comparison of Sentinel Lymph Node Biopsy Alone and Completion Axillary Lymph Node Dissection for Node-Positive Breast Cancer,” Journal of Clinical Oncology, Vol. 27, No. 18, 2009, pp. 2946-2953.

[13]   M. Greco, R. Agresti, N. Cascinelli, P. Casalini, R. Giovanazzi, A. Maucione, G. Tomasic, C. Ferraris, M. Ammatuna, S. Pilotti and S. Menard, “Breast Cancer Patients treated without Axillary Surgery: Clinical Implications and Biologic Analysis,” Annals of Surgery, Vol. 232, No. 1, 2000, pp. 1-7.

[14]   A. M. Naik, J. Fey, M. Gemignani, A. Heerdt, L. Montgomery, J. Petrek, E. Port, V. Sacchini, L. Sclafani, K. VanZee, R. Wagman, P. I. Borgen and H. S. Cody 3rd, “The Risk of Axillary Relapse after Sentinel Lymph Node Biopsy for Breast Cancer Is Comparable with That of Axillary Lymph Node Dissection: A Follow-Up Study of 4008 Procedures,” Annals of Surgery, Vol. 240, No. 3, 2004, pp. 462-468.

[15]   J. Park, J. V. Fey, A. M. Naik, P. I. Borgen, K. J. Van Zee and H. S. Cody 3rd, “A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-Positive Breast Cancer Patients Is Associated with the Use of a Multivariate Nomogram,” Annals of Surgery, Vol. 245, No. 3, 2007, pp. 462-468.

[16]   L. Spiguel, K. Yao, D. J. Winchester, A. Gorchow, H. Du, S. F. Sener, B. Martz, M. Turk, E. Barrera and D. P. Winchester, “Sentinel Node Biopsy Alone for NodePositive Breast Cancer: 12-Year Experience at a Single Institution,” Journal of the American College of Surgeons, Vol. 213, No. 1, 2011, pp. 122-128.

[17]   H. Joensuu and J. Gligorov, “Adjuvant Treatments for Triple-Negative Breast Cancers,” Annals of Oncology, Vol. 23, Suppl. 6, 2012, pp. vi40-vi45.

[18]   A. S. Coates, M. Colleoni and A. Goldhirsch, “Is Adjuvant Chemotherapy Useful for Women with Luminal a Breast Cancer?” Journal of Clinical Oncology, Vol. 30, No. 12, 2012, pp. 1260-1263.